CASP3 and neoplasm: Finally, and in agreement with our DAVID analysis, showing that the regulation of cell death and proliferation were significantly affected by acadesine-rituximab combination in MCL tumors, by immunohistochemistry we observed a higher expression of the activated form of caspase-3 (figure 4C, panel act.Casp3) and a reduction in the phosphorylation status of the proliferation marker histone H3 (figure 4C, panel Phospho-H3), in the tumor tissues treated with acadesine plus rituximab, when compared to vehicle- and single agent-treated tumors.